Philippe Devillier1, Mathieu Molimard2, Xavier Ansolabehere3, Isabelle Bardoulat3, Nicolas Coulombel3, Frédérique Maurel3, Philippe Le Jeunne3, Pascal Demoly4,5. 1. UPRES EA 220, Department of Airway Diseases, Hospital Foch, University of Versailles Saint Quentin, University Paris-Saclay, Suresnes, France. 2. Pharmacology Department, University of Bordeaux, INSERM Unit CR1219, Bordeaux, France. 3. Real-World Insights Department, IQVIA, La Défense, France. 4. Department of Pulmonology and Addictology, Arnaud de Villeneuve Hospital, Montpellier University, Montpellier, France. 5. Sorbonne Universités, UPMC, Paris 06, UMR-S 1136, INSERM, IPLESP, Equipe EPAR, Paris, France.
Abstract
BACKGROUND: Moderate-to-severe allergic rhinitis (AR) may increase the risk of developing or worsening asthma, whereas treatment of AR with subcutaneously or sublingual allergen immunotherapy (SLIT) may slow this progression. METHODS: In a retrospective real-world analysis, prescription fulfilment data were gathered from French retail pharmacies between 1 March 2012 and 31 December 2016. Using linear regression analyses, patients having received at least two prescriptions of grass pollen SLIT tablets over at least 2 successive years were compared with control patients having received symptomatic medications only. RESULTS: A total of 1099 SLIT patients and 27 475 control patients were included in the main analysis. With regard to symptomatic AR medication dispensing, we observed a 50% decrease in the pre-index/follow-up ratio in the SLIT group, a 30% increase in the control group without age matching (P < 0.0001 vs SLIT) and a 20% increase in the control group with age matching (P < 0.0001 vs SLIT). During the follow-up, 11 (1.8%) and 782 (5.3%) patients initiated asthma treatment in the SLIT and control groups, respectively. The relative risk of medication dispensing for new asthma was lower in the SLIT group (by 62.5% [29.1%-80.1%] without age matching (P = 0.0025) and by 63.7% [31.5%-80.7%] with age matching; P = 0.0018). SLIT was also associated with slower progression of asthma medication dispensing during the follow-up period, relative to the control group (regression coefficient: -0.58 [-0.74 to 0.42] without age matching (P < 0.0001) and -0.61 [-0.76 to -0.46] with age matching; P < 0.0001). CONCLUSION: Prescription of grass pollen SLIT tablets reduced the dispensing of AR and asthma medications in real life.
BACKGROUND: Moderate-to-severe allergic rhinitis (AR) may increase the risk of developing or worsening asthma, whereas treatment of AR with subcutaneously or sublingual allergen immunotherapy (SLIT) may slow this progression. METHODS: In a retrospective real-world analysis, prescription fulfilment data were gathered from French retail pharmacies between 1 March 2012 and 31 December 2016. Using linear regression analyses, patients having received at least two prescriptions of grass pollen SLIT tablets over at least 2 successive years were compared with control patients having received symptomatic medications only. RESULTS: A total of 1099 SLIT patients and 27 475 control patients were included in the main analysis. With regard to symptomatic AR medication dispensing, we observed a 50% decrease in the pre-index/follow-up ratio in the SLIT group, a 30% increase in the control group without age matching (P < 0.0001 vs SLIT) and a 20% increase in the control group with age matching (P < 0.0001 vs SLIT). During the follow-up, 11 (1.8%) and 782 (5.3%) patients initiated asthma treatment in the SLIT and control groups, respectively. The relative risk of medication dispensing for new asthma was lower in the SLIT group (by 62.5% [29.1%-80.1%] without age matching (P = 0.0025) and by 63.7% [31.5%-80.7%] with age matching; P = 0.0018). SLIT was also associated with slower progression of asthma medication dispensing during the follow-up period, relative to the control group (regression coefficient: -0.58 [-0.74 to 0.42] without age matching (P < 0.0001) and -0.61 [-0.76 to -0.46] with age matching; P < 0.0001). CONCLUSION: Prescription of grass pollen SLIT tablets reduced the dispensing of AR and asthma medications in real life.
Authors: Bernardo Sousa-Pinto; Luís Filipe Azevedo; Ana Sá-Sousa; Rafael José Vieira; Rita Amaral; Ludger Klimek; Wienczyslawa Czarlewski; Josep M Anto; Anna Bedbrook; Violeta Kvedariene; Maria Teresa Ventura; Ignacio J Ansotegui; Karl-Christian Bergmann; Luisa Brussino; G Walter Canonica; Victoria Cardona; Pedro Carreiro-Martins; Thomas Casale; Lorenzo Cecchi; Tomás Chivato; Derek K Chu; Cemal Cingi; Elisio M Costa; Alvaro A Cruz; Giulia De Feo; Philippe Devillier; Wytske J Fokkens; Mina Gaga; Bilun Gemicioğlu; Tari Haahtela; Juan Carlos Ivancevich; Zhanat Ispayeva; Marek Jutel; Piotr Kuna; Igor Kaidashev; Helga Kraxner; Désirée E Larenas-Linnemann; Daniel Laune; Brian Lipworth; Renaud Louis; Michaël Makris; Riccardo Monti; Mario Morais-Almeida; Ralph Mösges; Joaquim Mullol; Mikaëla Odemyr; Yoshitaka Okamoto; Nikolaos G Papadopoulos; Vincenzo Patella; Nhân Pham-Thi; Frederico S Regateiro; Sietze Reitsma; Philip W Rouadi; Boleslaw Samolinski; Milan Sova; Ana Todo-Bom; Luis Taborda-Barata; Peter Valentin Tomazic; Sanna Toppila-Salmi; Joaquin Sastre; Ioanna Tsiligianni; Arunas Valiulis; Dana Wallace; Susan Waserman; Arzu Yorgancioglu; Mihaela Zidarn; Torsten Zuberbier; João Almeida Fonseca; Jean Bousquet; Oliver Pfaar Journal: Clin Transl Allergy Date: 2022-03 Impact factor: 5.871
Authors: L Klimek; R Brehler; R Mösges; P Demoly; J Mullol; D Y Wang; R E O'Hehir; A Didier; M Kopp; C Bos; E Karagiannis Journal: Hum Vaccin Immunother Date: 2022-06-15 Impact factor: 4.526
Authors: Danilo Di Bona; Giovanni Paoletti; Derek K Chu; Jack Pepys; Luigi Macchia; Enrico Heffler; Giorgio Walter Canonica Journal: Clin Transl Allergy Date: 2021-06-14 Impact factor: 5.871
Authors: Jorn J Heeringa; Craig I McKenzie; Nirupama Varese; Mark Hew; Amy T C M Bakx; Pei M Aui; Jennifer M Rolland; Robyn E O'Hehir; Menno C van Zelm Journal: Allergy Date: 2019-11-04 Impact factor: 13.146